2.36
+4.42%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pacific Biosciences of California
From its filings with the US Securities and Exchange Commission
Pacific Biosciences of California is based in Menlo Park, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PACB. The SEC classifies its business as laboratory analytical instruments. In the fiscal year to 31 December 2025, it reported revenue of $160.0m and a net loss of $546.4m. At that date it held total assets of $784.1m and shareholders' equity of $5.3m.
We are a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.
Our products and technology, which include our HiFi long-read sequencing technology, address a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.
Our focus is on creating some of the world's most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes.
Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations ("CROs"), pharmaceutical companies, and agricultural companies.
On January 30, 2026, we completed the disposition of assets to Illumina Cambridge Limited (the “Buyer”) in accordance with the terms of an Asset Purchase Agreement, dated January 30, 2026 (the “Asset Purchase Agreement”), by and among us, Buyer, and Illumina, Inc.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 27 Oct 2010
- Employees
- 485
- Website
- pacb.com ↗
- Head office
- 1305 O'BRIEN DRIVE, MENLO PARK, CA, 94025
- Incorporated in
- DE
- Classification
- Laboratory Analytical Instruments
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Dr. John MilliganIndependent Chairman of the Board$172,311
- Mr. Christian HenryPresident, Chief Executive Officer, Director, since 2018$9.2m
- Mr. Jim GibsonChief Financial Officer, Principal Financial Officer
- Mr. Mark Van OeneChief Operating Officer$4.8m
- Dr. Christopher GibsonDirector
- Mr. William EricsonIndependent Director$134,311
- Mr. Randall LivingstonIndependent Director$140,311
- Mr. Marshall MohrIndependent Director$132,311
- Ms. Kathy OrdonezIndependent Director, since 2014$132,311
- Dr. Lucy ShapiroIndependent Director$130,311
- Mr. Christopher SmithIndependent Director
- Dr. Hannah ValantineIndependent Director$125,311
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 16
- Social
- 60
- Governance
- 51
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pacific Biosciences of California Inc is known for its strong focus on technological innovation in the field of genetic sequencing. By developing cutting-edge sequencing platforms and technologies, the company has established itself as a leader in the industry, showcasing their ability to stay ahead of competitors.
- The company boasts a robust intellectual property portfolio, which grants it a competitive advantage and protection against potential lawsuits or infringement claims. With a wide range of patents and exclusive rights, Pacific Biosciences of California Inc can safeguard its innovative discoveries and maintain a strong market position.
Weaknesses
- One of the critical weaknesses of Pacific Biosciences of California Inc is its reliance on external funding sources. The company heavily depends on government grants and partnerships for research and development activities, which exposes it to potential funding uncertainties and limitations. This reliance on external sources can disrupt long-term planning and hinder the company's growth prospects.
- Despite being a key player in the genetic sequencing industry, Pacific Biosciences of California Inc has a relatively limited market reach. The company primarily targets research institutions, academic organizations, and some pharmaceutical companies. Expanding their customer base beyond these segments could be a challenge and may restrict their revenue potential in other market sectors.
Opportunities
- The increasing demand for genetic sequencing in various fields, including healthcare, agriculture, and biotechnology, presents a significant opportunity for Pacific Biosciences of California Inc. By capitalizing on this trend, the company can expand its customer base and increase revenue streams.
- There is a potential for Pacific Biosciences of California Inc to form strategic partnerships with key players in related industries. Collaborating with pharmaceutical companies, diagnostic labs, or instrument manufacturers can provide access to new markets, enhance product offerings, and lead to mutually beneficial business opportunities.
Threats
- Pacific Biosciences of California Inc faces intense competition from well-established competitors in the genetic sequencing market. The presence of companies with greater resources, market share, and brand recognition can pose a threat to the company's growth and market penetration efforts.
- The genetic sequencing industry is subject to various regulatory and legal challenges, including compliance with data privacy laws, intellectual property disputes, and ethical considerations. Pacific Biosciences of California Inc must navigate these challenges carefully to avoid legal complications and maintain ethical practices.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.